Semaglutide and Weight Loss: What the Trials Actually Show

What the claim says

Medicines based on the gut hormone GLP-1 reduce appetite and cause substantial weight loss in people with obesity.

What the evidence shows

Multiple large, well-run, placebo-controlled trials, lasting over a year, report average losses in the range of 10 to 15 percent of body weight, with improvements in several heart and metabolic markers. Some trials also show fewer major cardiovascular events in selected groups.

The fine print

• Nausea and other digestive effects are common, especially early on.
• Follow-up trials show much of the weight returns after stopping.
• These are prescription drugs with a medical selection process.

A strong result in a trial population does not make a product bought elsewhere the same thing.

Verdict

Solid for the approved medicines used under medical care. It says nothing about unregulated "research" versions.

Bottom line

• This is among the best-evidenced peptide claims.
• It applies to regulated products and supervised use.
• Stopping the drug usually means regaining weight.